]>
IRCT20160523028008N13 IRCT 2021-03-21 Iran University of Medical Sciences Induction of abortion in the first trimester by misoprostol or misoprostol with different dose of letrozo Induction of abortion in the first trimester by misoprostol or misoprostol with different dose of letrozol In women referring to Akbarabadi hospital in 1398-1399 2021-05-05 anticipated 114 Complete https://irct.ir/trial/54861 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients will be randomly assigned to interventions and control groups using block randomization. For this purpose, we will prepare six sheets of paper, writing on four sheets the name of the intervention and on the other two sheets the name of the control. The paper sheets will be pooled, placed in a container, and randomly drawn one at a time for each patient without replacement until all four sheets are drawn. The six paper sheets will be then placed back into the container, and this action repeated until the sample size is reached, Blinding description: Patients are not aware of the type of intervention, so the study is a one-way blind. 2-3 Medical abortion. Intervention 1: Intervention group: Letrozole 10 mg and misoprostol tablets 800 mg three doses at intervals of three hours vaginal made by Abureyhan Pharmaceutical Company, Iran. Intervention 2: Intervention group: Letrozole 5 mg and misoprostol tablets 800 mg three doses at intervals of three hours vaginal made by Abureyhan Pharmaceutical Company, Iran. Intervention 3: Control group: Placebo and misoprostol tablets 800 mg three doses at intervals of three hours vaginal made by Abureyhan Pharmaceutical Company, Iran. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is not a plan to make this available
public Mojgan Mokhtari
shahid Akbar Abadi Hospital,Ferdowsi Station, Molavi st, Tehran
Tehran Iran (Islamic Republic of) 1168743514 +98 21 6655 2972 mokhtari.m@iums.ac.ir Iran University of Medical Sciences scientific Mojgan Mokhtari
Shahid Akbar Abadi Hospital,Ferdowsi Station, Molavi st, Tehran
Tehran Iran (Islamic Republic of) 1168743514 +98 912 761 1381 mokhtari.m@iums.ac.ir Iran University of Medical Sciences Iran (Islamic Republic of) Age older than 18 years Gestational age based on ultrasound findings less than 12 weeks Patient and spouse satisfaction Lack of systemic diseases such as hypertension, kidney disease Hemoglobin greater than or equal to 10 g / l, diastolic blood pressure less than 95 mm Hg 18 years no limit Female Having an IUD Any allergy to letrozole or misoprostol Liver disease, kidney failure, high blood pressure and asthma Convulsions O08.9 Complication following abortion and ectopic and molar pregnancy,unspecified Treatment - Drugs Treatment - Drugs Treatment - Drugs Intervention group: Letrozole 10 mg and misoprostol tablets 800 mg three doses at intervals of three hours vaginal made by Abureyhan Pharmaceutical Company, Iran Intervention group: Letrozole 5 mg and misoprostol tablets 800 mg three doses at intervals of three hours vaginal made by Abureyhan Pharmaceutical Company, Iran Control group: Placebo and misoprostol tablets 800 mg three doses at intervals of three hours vaginal made by Abureyhan Pharmaceutical Company, Iran The interval between induction and abortion beginning and opening of cervical internal os. Timepoint: Until 24 hours after receiving Misoprostol, every 1 hou. Method of measurement: Sonography. The interval between induction and complete abortion. Timepoint: Until 24 hours after receiving Misoprostol, every 1 hour. Method of measurement: Sonography. Gastrointestinal problems (nausea or vomiting). Timepoint: From receiving Letrozole until 24 hours after receiving Misoprostol. Method of measurement: Objective. Iran University of Medical Sciences Approved 2021-02-21 Iran University of Medical Sciences Iran University of Medical Sciences, Hemmat High Way Tehran Tehran Iran (Islamic Republic of)